Vincent Rajkumar: My Top 5 ASH24 myeloma abstracts
Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester, shared a post on X:
“Here are my Top 5 ASH24 myeloma abstracts. My Top 5 are based on new data, clinical impact, and methodology.
5. UPEP 24 hour urine protein study is not necessary for response assessment in myeloma. Serum FLC takes its place. Will save a lot of dollars and time, and reduce protocol violations.
Authors: Rahul Banerjee, Amber R. Fritz, Othman S Akhtar, Ciara Louise Freeman, Andrew J. Cowan, Nina Shah, Heather J. Landau, Shaji Kumar, Dan T. Vogl, Yvonne A. Efebera, Philip L. McCarthy, David H. Vesole, Adam Mendizabal, Amrita Y Krishnan, George Somlo, Edward A. Stadtmauer, and Marcelo C. Pasquini,
4. Efficacy of a new trispecific antibody in relapsed refractory myeloma: ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific. Immunotherapy has revolutionized myeloma therapy and we have continued progress.
Authors: Hang Quach, Bradley Augustson, Hanlon Sia, Nishi Shah, Eben I Lichtman, Michaela Liedtke, Camille Martinet, Vinu Menon, Andrew Garton, Maria Pihlgren, Beata Holkova, Cyril Konto, Lida Pacaud, Amit Khot,
3. Daratumumab plus Lenalidomide – a dexamethasone free regimen for newly diagnosed myeloma. Reduced risk of progression by 50%. Important new option for elderly, frail patients who cannot tolerate quads
Authors: Salomon Manier, Jérome Lambert, Cyrille Hulin, Kamel Laribi, Carla Araujo, Gian Matteo Pica, Cyrille Touzeau, Pascal Godmer, Bohrane Slama, Lionel Karlin, Frederique Orsini Piocelle, Mamoun Dib, Magaret Macro, Laurence Sanhes, Lydia Montes, Abderrazak El Yamani, Mourad Tiab, Reza Tabrizi, Laurent Garderet, Bruno Royer, Benoit Bareau, Aurore Perrot, Jean Yves Mary, Jill Corre, Herve Avet Loiseau, Philippe Moreau, Xavier Leleu, Thierry Facon
2. Anitocabtagene Autoleucel for Relapsed Refractory Myeloma: IMMagine-1 Trial results. New CAR-T for myeloma. Registration study. Impressive results.
Authors: Ciara Louise Freeman, Binod Dhakal, Gurbakhash Kaur, Richard T. Maziarz, Natalie Callander, Adam S. Sperling, Carolina Schinke, Andrzej J Jakubowiak, Noa Biran, Douglas W Sborov, Cindy Varga, Abhinav Deol, Abraham S. Kanate, Mehmet Hakan Koçoğlu, Melhem M. Solh, Kamalika Banerjee, Rebecca Chan, Myrna Nahas, Ana Kostic, Enrique Granados, Carolyn Jackson, Christopher R. Heery, Tim Welliver, Krina K. Patel, Matthew Frigault,
1. Isatuximab-VRd vs VRd Induction for Newly Diagnosed Myeloma: Phase 3 GMMG-HD7.
Well designed RCT. More to come in Part 2 later. Along with other RCTs, establishes quads as standard frontline for myeloma.
Authors: Hartmut Goldschmidt, Uta Bertsch, Ema Pozek, Axel Benner, Roland Fenk, Britta Besemer, Christine Hanoun, Roland Schroers, Ivana von Metzler, Mathias Hänel, Christoph Mann, Lisa Leypoldt, Bernhard Heilmeier, Stefanie Huhn, Sabine Vogel, Michael Hundemer, Christof Scheid, Igor Wolfgang Blau, Steffen Luntz, Tobias A.W. Holderried, Karolin Trautmann-Grill, Deniz Gezer, Maika Klaiber-Hakimi, Martin Mueller, Evgenii Shumilov, Wolfgang Knauf, Christian Sebastian Michel, Thomas Geer, Hendrik Riesenberg, Christoph Lutz, Marc-Steffen Raab, Martin Hoffmann, Katja C. Weisel, Hans Salwender, Elias K. Mai,
As in the past, I left out studies where similar results were already presented or published before. I also excluded the AQUILA trial in which I’m a lead investigator and senior author when making this list. —That’s for others to decide.
As usual, I will post updated algorithms on How I Treat Myeloma taking into account ASH24 data, later during the meeting. Follow for other critiques and updates.”
More posts featuring Vincent Rajkumar.
Vincent Rajkumar is a Professor of Medicine at the Mayo Clinic in Rochester, Minnesota, and Chair for the Mayo Clinic Myeloma, Amyloidosis, and Dysproteinemia Group. He also chairs the Board of directors of The International Myeloma Foundation and the Eastern Cooperative Oncology Group (ECOG) Myeloma Committee.
His extensive contributions include over 230 peer-reviewed publications, predominantly focusing on multiple myeloma and related plasma cell disorders. Furthermore, Dr. Rajkumar is a Section Editor for multiple myeloma and related disorders for Leukemia and an Associate Editor for the Mayo Clinic Proceedings.
Further Reading:
The 66th American Society of Hematology (ASH) Annual Meeting and Exposition
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023